# Cardurion Pharmaceuticals: Research, Burlington, United States

> Cardurion Pharmaceuticals: Cardurion Pharmaceuticals is a clinical-stage biotechnology company founded in 2017, focused on developing innovative...

Source: https://millionrounds.com/startup/cardurion-pharmaceuticals (Millionrounds; every figure on the page links to its filing or article)

United States · [Research startup](https://millionrounds.com/companies)

# Cardurion Pharmaceuticals

Cardurion Pharmaceuticals is a clinical-stage biotechnology company founded in 2017, focused on developing innovative therapeutics for heart failure and other cardiovascular diseases.

Funding reported Last round: Series B

Research Burlington, United States

Company summary

- **Founded:** 2017 9 years old
- **Team:** 74 51 to 200 people
- **Funding reported:** $603M in dollars
- **Last round:** Series B Jul 2024

How sure we are

- ✓ **Listed** We know it exists and what it does
- 2 **Funding reported** A company dataset reports a raise
- 3 **Observed** A filing or a dated announcement confirms a round

No round for Cardurion Pharmaceuticals has been confirmed by a filing or an announcement yet, so nothing here counts toward an investor's record. [How we decide](https://millionrounds.com/methodology)

## About Cardurion Pharmaceuticals

Cardurion Pharmaceuticals is a clinical-stage biotechnology company founded in 2017, focused on developing innovative therapeutics for heart failure and other cardiovascular diseases.

The company is advancing two key clinical programs: CRD-750, a PDE9 inhibitor targeting heart failure, and CRD-4730, the first CaMKII inhibitor aimed at multiple cardiovascular indications. Both candidates are currently in Phase 2 clinical trials. Headquartered in Burlington, Massachusetts, Cardurion operates a preclinical drug discovery unit in Shonan, Japan. The company was established by physician-scientist Michael E. Mendelsohn and a team of experts in cardiovascular signaling pathways. Cardurion is privately held and has received significant investments, including $300 million from Bain Capital Life Sciences and $260 million in a Series B funding round led by Ascenta Capital. The company is dedicated to transforming cardiovascular disease treatment through deep scientific research and innovation.

## What company datasets say Cardurion Pharmaceuticals raised

Funding, as reported

Reported in all **$603M** in dollars

Rounds **6**

Last round **Series B**

Last round size **$260M**

Last round date **Jul 2024**

Investors listed **14**

SEC Form D **$478M sold, 6 filings, last Jul 2024**

## Founders and team

From Cardurion Pharmaceuticals's own website: 4 on the team.

- **Charlotte Newman** Chief Business & Operating Officer
- **Karen Lewis** Chief People Officer
- **Emma Reeve** Director
- **Ron Renaud** Chairman

## On 3 portfolio pages

Investors who name them

- [Delos Capital](https://millionrounds.com/fund/delos-capital)
- [Ascenta Capital](https://millionrounds.com/fund/ascenta-capital)
- [Bain Capital Private Equity](https://millionrounds.com/fund/bain-capital-private-equity)

Each firm lists Cardurion Pharmaceuticals on its own website. That is the firm's claim, a weaker thing than a round we watched, but a named source.

## The company, in detail

What they build

Known for

biotechnology research cardiology heart failure medical biotechnology cardiovascular b2b therapeutics

Built with from their website

Airtable DocuSign Adobe Smartsheet Zoom Meetings Zendesk for Service Cisco Webex Control Hub Amazon AWS Microsoft Exchange Online OpenAI

+8 more

Apple Business Manager Zendesk KnowBe4 Microsoft Exchange Microsoft 365 AWS Cloud Outlook Microsoft 365 Apps & Services

- **Sector:** Research
- **Industry code:** NAICS 541714, SIC 8731
- **Region:** Massachusetts
- **Revenue:** $5.8M a year, as listed
- **Full record:** [Every detail in the company directory](https://millionrounds.com/directory/cardurion-pharmaceuticals)

## Research in United States

Startups like it

- [**OpenAI** San Francisco · founded 2011 *Raised*](https://millionrounds.com/company/openai)
- [**Retro Biosciences** Redwood City · founded 2021 *Raised*](https://millionrounds.com/company/retro-biosciences)
- [**NewLimit** South San Francisco · founded 2022 *Raised*](https://millionrounds.com/company/newlimit)
- [**Pathos** New York · founded 2022 *Raised*](https://millionrounds.com/company/pathos)
- [**Colossal Biosciences** Dallas · founded 2021 *Raised*](https://millionrounds.com/company/colossal-biosciences)
- [**Oratomic** South Pasadena *Raised*](https://millionrounds.com/company/oratomic)
- [**Beeline Medicines** Stamford · founded 2025 *Raised*](https://millionrounds.com/company/beeline-medicines)
- [**Element Biosciences** San Diego · founded 2017 *Raised*](https://millionrounds.com/company/element-biosciences)

## Is this your company?

Add your raise, your deck and your story, and put Cardurion Pharmaceuticals in front of investors. Or tell us what we have wrong.

[List your startup](https://millionrounds.com/list-your-startup)[Send a correction](https://millionrounds.com/corrections)